158 related articles for article (PubMed ID: 12084473)
1. Preferential targeting of apoptosis in tumor versus normal cells.
Woynarowska BA; Woynarowski JM
Biochim Biophys Acta; 2002 Jul; 1587(2-3):309-17. PubMed ID: 12084473
[TBL] [Abstract][Full Text] [Related]
2. DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells.
Faivre S; Chan D; Salinas R; Woynarowska B; Woynarowski JM
Biochem Pharmacol; 2003 Jul; 66(2):225-37. PubMed ID: 12826265
[TBL] [Abstract][Full Text] [Related]
3. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent.
Herzig MC; Trevino AV; Liang H; Salinas R; Waters SJ; MacDonald JR; Woynarowska BA; Woynarowski JM
Biochem Pharmacol; 2003 Feb; 65(4):503-13. PubMed ID: 12566077
[TBL] [Abstract][Full Text] [Related]
5. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
[TBL] [Abstract][Full Text] [Related]
6. Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor model.
Kelner MJ; McMorris TC; Rojas RJ; Estes LA; Suthipinijtham P
Cancer Chemother Pharmacol; 2008 Dec; 63(1):19-26. PubMed ID: 18305940
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells.
Ozdian T; Holub D; Maceckova Z; Varanasi L; Rylova G; Rehulka J; Vaclavkova J; Slavik H; Moudry P; Znojek P; Stankova J; de Sanctis JB; Hajduch M; Dzubak P
J Proteomics; 2017 Jun; 162():73-85. PubMed ID: 28478306
[TBL] [Abstract][Full Text] [Related]
8. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
9. Cellular processing of platinum anticancer drugs.
Wang D; Lippard SJ
Nat Rev Drug Discov; 2005 Apr; 4(4):307-20. PubMed ID: 15789122
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin triggers necrosis as well as apoptosis in gastric cancer SGC-7901 cells.
Wu P; Zhu X; Jin W; Hao S; Liu Q; Zhang L
Biochem Biophys Res Commun; 2015 May; 460(2):183-90. PubMed ID: 25767076
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
O'Neill CF; Ormerod MG; Robertson D; Titley JC; Cumber-Walsweer Y; Kelland LR
Br J Cancer; 1996 Oct; 74(7):1037-45. PubMed ID: 8855971
[TBL] [Abstract][Full Text] [Related]
12. Copper-redox cycling by coumarin-di(2-picolyl)amine hybrid molecule leads to ROS-mediated DNA damage and apoptosis: A mechanism for cancer chemoprevention.
Khan S; Zafar A; Naseem I
Chem Biol Interact; 2018 Jun; 290():64-76. PubMed ID: 29803612
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated NADH oxidase (tNOX)-NAD+-sirtuin 1 axis contributes to oxaliplatin-induced apoptosis of gastric cancer cells.
Chen HY; Cheng HL; Lee YH; Yuan TM; Chen SW; Lin YY; Chueh PJ
Oncotarget; 2017 Feb; 8(9):15338-15348. PubMed ID: 28122359
[TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
[TBL] [Abstract][Full Text] [Related]
16. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA.
Shou J; Ali-Osman F; Multani AS; Pathak S; Fedi P; Srivenugopal KS
Oncogene; 2002 Jan; 21(6):878-89. PubMed ID: 11840333
[TBL] [Abstract][Full Text] [Related]
17. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
[TBL] [Abstract][Full Text] [Related]
18. Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets.
Pervaiz S
Curr Pharm Des; 2006; 12(34):4469-77. PubMed ID: 17168754
[TBL] [Abstract][Full Text] [Related]
19. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Qin X; Fang L; Chen F; Gou S
Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
Woynarowski JM; Woynarowska BA; Trevino AV; Salinas R; Herman TS; Waters SJ; Macdonald JR
Cancer Biol Ther; 2004 Nov; 3(11):1137-42; discussion 1143-4. PubMed ID: 15467441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
